The most prevalent non-BRCA tumor mutations are TP53 and PIK3CA. BRCA LOH is evident in 85% of tBRCAmut patients evaluable for BRCA zygosity and 81.6% of patients have gLOH ≥16% across both cohorts. This evidence concerns the gene PIK3CA and neoplasm.